Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older at the time of screening.
- People who have been diagnosed with either advanced endometrial cancer (uterine cancer) at a late stage, or endometrial cancer that has come back and cannot be cured, where the medical team has decided that drug treatment is the right approach. A type of cancer called carcinosarcoma is also included.
- People who are planned to receive, or have already started, a specific combination of cancer treatments: chemotherapy (carboplatin and paclitaxel) followed by a maintenance treatment with durvalumab (brand name IMFINZI®), or durvalumab together with olaparib (brand name Lynparza®), based on the approved guidelines for these medicines. People who have already received up to 2 cycles of chemotherapy may still be considered, though places for this group are limited.
- People whose tumour is eligible for treatment with durvalumab and/or olaparib according to the approved prescribing guidelines for IMFINZI® and Lynparza® (confirm with trial site).
- People whose tumour has already been tested for a specific feature called MMR (mismatch repair) status, with results available.
- People who are willing and able to fill in quality-of-life questionnaires as part of the study.
- People who can read and understand German, English, Arabic, Russian, or Turkish.
- People who have signed a written consent form agreeing to take part.
Who may not be able to join:
- People who have already received more than 2 cycles of the first-line chemotherapy combination.
- People with a known allergy or sensitivity to carboplatin, paclitaxel, durvalumab, olaparib, or any of the ingredients in these medicines.
- People who are pregnant or currently breastfeeding.
- People who are unable to swallow tablets or capsules.
- People who are currently taking part in, or planning to take part in, another interventional clinical trial.
- People who are currently receiving or planning to receive drug treatment for a different type of cancer other than the endometrial cancer described above.
- People whose cancer has been identified as a sarcoma.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Real-world Time To Next Treatment (rwTTNT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.